AZ-SUPIMA/TEXTILEGENESIS
13.6.2022 10:02:09 CEST | Business Wire | Press release
Supima, the brand for American-grown Pima cotton, announces a strategic partnership with TextileGenesis™ to establish the new industry benchmark platform for authenticating cotton.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220613005099/en/
The Supima blockchain platform powered by TextileGenesis™ will digitally connect Supima’s comprehensive supply chain from the growers to the brand/retailers. Integrated with this digital platform, Supima’s technology partner Oritain™ will provide the forensic origin authentication for Supima cotton across the platform. The ability to independently validate the Supima content of products at every stage of the supply chain achieves unmatched authenticity and responsibility through the combination of forensic physical and digital authentication.
Since it was founded in 1954, SUPIMA® has been referred to as the “world’s finest cottons.” Today marks the next chapter in Supima’s ongoing leadership role in bringing the most trusted and robust verification solution to authentic premium fiber sourcing to the global fashion industry. SUPIMA® is fortunate to partner with brands and retailers that are leaders in transparency and responsible sourcing. This ground-breaking supply chain traceability platform will provide an underlying mechanism to collaborate with the partners in a transparent, and verifiable way.
TextileGenesis’ Fibercoin™ technology will be integrated into Supima’s licensing program and applied to all SUPIMA® branded fiber throughout the supply chain, creating a non-fungible digital token for every kilogram of Supima cotton that can be physically and forensically verified and authenticated by Supima from the farm through to the retail shelf. This pioneering effort for cotton sourcing sets a new standard for responsibility in the global textile industry and consumer marketplace. Supima is striving to bring deeper levels of authenticity and responsibility to cotton sourcing with greater support for equity and ubiquity for all partners in the supply chain.
“The Supima partnership with TextileGenesis provides for the very first time, undisputable proof of origin for consumer products all the way back to the fiber’s origin. This enables Supima’s partner brands to credibly claim advantages in terms of product quality and sustainability that are independently verifiable through both digital and forensic testing. There is no system like this for any other fiber. SUPIMA® partners will have the most authentic and trustworthy premium cotton source for all the current and future needs of luxury apparel and home textile products,” says Marc Lewkowitz, President and CEO of Supima.
“This collaboration is setting a new benchmark for the cotton and premium fiber’s industry, and paves a new path for the entire fashion eco-system. We are creatively combining three major innovations - digital-tokens based article-level traceability, forensic physical verification, and Supima brand-licensing - in a single integrated platform. It creates a new platinum standard in the industry for end-to-end traceability and physical verification,” says Amit Gautam, Founder and CEO of TextileGenesis.
ABOUT TEXTILEGENESIS
TextileGenesis is a market-leading traceability platform custom-built for the fashion and textile ecosystem. It has partnered with 40+ leading global brands to create fiber-to-retail traceability for sustainable, premium and certified materials. By the end of 2022, TextileGenesis will create traceability for 500 million+ units in the global fashion industry.
ABOUT SUPIMA
Supima is America’s luxury cotton: founded in 1954, the Supima brand, short for “Superior Pima,” designates an exclusive source of exceptional extra-long staple cotton responsibly grown only in the West and the Southwestern U.S. It is prized the world over by designers and discerning consumers who value its resilient strength, lasting color, indulgent softness, and durability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220613005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
